Summary of Key Points Core Viewpoint - The company has announced the provision for asset impairment for the first half of 2025, reflecting a need to accurately represent its financial status and operational results as of June 30, 2025 [1][2]. Group 1: Asset Impairment Provision Overview - The company conducted impairment testing on various assets as of June 30, 2025, resulting in a total asset impairment provision of 60.6191 million RMB [1]. - The breakdown of the impairment losses includes a credit impairment loss of 5.3914 million RMB and an asset impairment loss of 66.0105 million RMB [1]. Group 2: Specifics of the Impairment Provision - The company recognized impairment losses based on expected credit losses for accounts receivable, contract assets, and other receivables, leading to a total provision for bad debt [1]. - The impairment loss for long-term deferred expenses amounted to 10.4693 million RMB, indicating signs of impairment as of the balance sheet date [1]. - The provision will reduce the equity attributable to shareholders by 54.1420 million RMB as of June 30, 2025, and is in compliance with relevant accounting standards and company policies [2].
昭衍新药: 昭衍新药2025年半年度计提资产减值准备公告